Newroom
Toekenning Industrial Doctorates subsidie
Samenwerking Sulfateq en UMCG erkent met een Industrial Doctorates subsidie Afgelopen augustus 2018 is door de Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) een Industrial Doctorate beurs toegekend aan een...
Kidney Week 2017
The international kidney week is right around the corner. From 31 October until 5 November 2017 more than 13.000 kidney professionals from across the globe will come to New Orleans to exchange knowledge about the fight against kidney disease. Acute...
New publication SUL-121 compound
In the range of compounds for protecting organs from Sulfateq a new paper is published. We are proud to announce that Dr. L.E. (Leo) Deelman (UMCG) has published his paper on the protective effects of our SUL-121 compound in diabetes. SUL-121...
Dr. Rob Henning on hibernation (BBC2)
Tonight (11 September 2017) please tune in to BBC2. At 22:00 (Dutch time), Professor Rob Henning of the UMCG discusses the need for human hibernation. In this episode of "The search for a new world" Christophe meets anaesthesiologist Dr. Rob...
Sepsis: a new application for the SUL-compounds?
Sulfateq B.V. is dedicated to developing new drugs for several diseases: Acute Kidney Injury (AKI), Chronic Obstructive Pulmonary Disease (COPD), Type II Diabetes (T2D) and obesity. We can now proudly announce that the SUL-compounds are being...
New publications ROKEPIE
Lately there is a lot of happening at Sulfateq which is very positive for the development of ROKEPIE. Besides our new website there are also multiple publications and papers which have been published or will be published in the near future. What’s...